A study led by UCL found that individuals with rare diseases were five times more likely to die from Covid-19 than the ...

Research analysts at StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a report released on Thursday. The brokerage set a “sell” rating on the ...

First up is the ADEPT study in bullous pemphigoid (BP), a rare skin condition ... with no relapse, and standard treatment with oral corticosteroids had been tailed off without the need for any ...

SG Americas Securities LLC increased its position in argenx SE (NASDAQ:ARGX – Free Report) by 6.2% in the 4th quarter, ...

EYLEA HD is anticipated to gain traction with the launch of a prefilled syringe in mid-2025 and label expansions for macular edema and extended dosing intervals. Management believes these developments ...

Finally, a supplementary BLA was submitted for bullous pemphigoid late last year ... total and food specific IgE levels following initial treatments at low doses. This trial is continuing to ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

The EU regulator is reviewing tralokinumab for the treatment of adult patients ... in chronic obstructive pulmonary disease (COPD), bullous pemphigoid, prurigo nodularis, chronic hives, and ...

Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in the ...